Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

University of Toronto

$17,500.00

Sensitizing quiescent medulloblastoma stem cells to anti-mitotic chemotherapy

FY 2018-19

Summary
Pediatric medulloblastoma (MB) is a brain cancer that arises in the cerebellum. Its treatment can damage developing brain tissue, leaving survivors with long-term health complications. It has been shown using a mouse model that MB tumours are driven by a rare population of quiescent cancer stem cells (CSCs) that differentiate to form the rapidly proliferating cells of the tumour bulk. Current chemotherapy drugs used to treat MB eradicate the tumour bulk, but CSCs are resistant to such treatment partially because of their quiescence. One mechanism that contributes to quiescence is regulation of resting membrane potential (RMP): the difference in ionic concentrations across a cell membrane at rest. Quiescent cells tend to be hyperpolarized relative to proliferating cells. Accordingly, MB CSCs have been observed to have a more negative RMP than the rapidly proliferating cells of the tumour bulk. I hypothesize that RMP hyperpolarization contributes to CSC quiescence and that perturbing the pathways that maintain this quiescent state will sensitize them to chemotherapy. Using a chemogenetics approach, I will depolarize and hyperpolarize CSCs in vitro and in vivo. I will test how changing RMP alters proliferation and differentiation. Next, to identify the molecular and genetic mechanisms underlying CSC quiescence and proliferation, I will perform transcriptomic and epigenetic analyses. Data from these experiments will allow me to uncover druggable pathways unique to CSCs that can disrupt their quiescence. The work proposed here aims to explore the unknown ways in which RMP contributes to CSC quiescence and develop a novel approach to selectively target the CSCs that potentiate MB tumours to treat and cure this cancer while minimizing collateral damage to the developing brain.
Program
Master's Award: Canada Graduate Scholarships
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
406468
Name
Dave Biren
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Sensitizing quiescent medulloblastoma stem cells to anti-mitotic chemotherapy
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Cancer; Chemotherapy; Drug Screen; Medulloblastoma; Quiescence; Stem Cells
Abstract
Pediatric medulloblastoma (MB) is a brain cancer that arises in the cerebellum. Its treatment can damage developing brain tissue, leaving survivors with long-term health complications. It has been shown using a mouse model that MB tumours are driven by a rare population of quiescent cancer stem cells (CSCs) that differentiate to form the rapidly proliferating cells of the tumour bulk. Current chemotherapy drugs used to treat MB eradicate the tumour bulk, but CSCs are resistant to such treatment partially because of their quiescence. One mechanism that contributes to quiescence is regulation of resting membrane potential (RMP): the difference in ionic concentrations across a cell membrane at rest. Quiescent cells tend to be hyperpolarized relative to proliferating cells. Accordingly, MB CSCs have been observed to have a more negative RMP than the rapidly proliferating cells of the tumour bulk. I hypothesize that RMP hyperpolarization contributes to CSC quiescence and that perturbing the pathways that maintain this quiescent state will sensitize them to chemotherapy. Using a chemogenetics approach, I will depolarize and hyperpolarize CSCs in vitro and in vivo. I will test how changing RMP alters proliferation and differentiation. Next, to identify the molecular and genetic mechanisms underlying CSC quiescence and proliferation, I will perform transcriptomic and epigenetic analyses. Data from these experiments will allow me to uncover druggable pathways unique to CSCs that can disrupt their quiescence. The work proposed here aims to explore the unknown ways in which RMP contributes to CSC quiescence and develop a novel approach to selectively target the CSCs that potentiate MB tumours to treat and cure this cancer while minimizing collateral damage to the developing brain.
Competitiondate
201812
Approvedterm2
1 yr 0 mth
Pinamesdelim
Dave, Biren
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~